Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered
Human content, AI powered search.

Latest Stories

FemSeven range of products set to return to market this year

Pb Staff writer
By Pb Staff writerFeb 02, 2021
Pb Staff writer
See Full Bio

Theramex has announced that its entire FemSeven portfolio of products will return to pharmacy shelves by mid-2021.

As of now, FemSeven Conti, one of the FemSeven portfolio of products, is available from Alliance Healthcare.

Earlier, non-patient-safety related quality issues were reported in the gradual withdrawal of the FemSeven portfolio from the market.

The company said in its latest update: “Theramex holds the marketing authorisation for FemSeven 50, 75 and 100 (estradiol), FemSeven Conti (estradiol/levonorgestrel) and FemSeven Sequi (estradiol/levonorgestrel) in the UK and Europe since acquiring these products from Teva Pharmaceuticals Ltd on February 1, 2018.

“…We have since been working diligently to fix these issues and are pleased confirm that the entire FemSeven® portfolio of products will be returning in 2021 commencing with FemSeven Conti® which is available now from Alliance Healthcare.”

Related News

NHS app to boost clinical trials
News

Government to use NHS app to boost clinical trials

Over four million flu vaccines across England in the 2024/25 winter flu season.
News

Community pharmacy administered over four million flu vaccines

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc